Stephens Inc. AR lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 2.4% during the fourth quarter, HoldingsChannel reports. The fund owned 178,887 shares of the biopharmaceutical company’s stock after acquiring an additional 4,155 shares during the quarter. Stephens Inc. AR’s holdings in Bristol-Myers Squibb were worth $10,962,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares in the last quarter. BlackRock Inc. raised its stake in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares in the last quarter. Dodge & Cox raised its stake in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after acquiring an additional 459,271 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after acquiring an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after acquiring an additional 910,496 shares in the last quarter. 70.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $67.92 on Friday. Bristol-Myers Squibb Co has a fifty-two week low of $51.56 and a fifty-two week high of $70.05. The firm has a market capitalization of $108,974.91, a P/E ratio of 115.12, a PEG ratio of 2.05 and a beta of 0.98. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is presently 271.19%.
Several brokerages have commented on BMY. Citigroup set a $78.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, February 16th. Jefferies Group set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, February 26th. DZ Bank downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, February 28th. Bank of America lifted their price target on Bristol-Myers Squibb from $64.00 to $68.00 and gave the stock a “neutral” rating in a research report on Monday, March 5th. Finally, ValuEngine downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $66.30.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II acquired 4,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3252934/bristol-myers-squibb-co-bmy-position-lifted-by-stephens-inc-ar.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.